Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in refractory CSU (POLARIS)
NCT02329223Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of omalizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Dec 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02329223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329223.